Patents by Inventor Andrew Lightfoot

Andrew Lightfoot has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240317821
    Abstract: The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
    Type: Application
    Filed: December 4, 2023
    Publication date: September 26, 2024
    Applicant: Revolo Biotherapeutics Limited
    Inventors: Andrew Lightfoot, Nicola Cooper, Donata Federici Canova
  • Patent number: 11834478
    Abstract: The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
    Type: Grant
    Filed: May 23, 2022
    Date of Patent: December 5, 2023
    Assignee: Revolo Biotherapeutics Limited
    Inventors: Andrew Lightfoot, Nicola Cooper, Donata Federici Canova
  • Publication number: 20230242596
    Abstract: The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
    Type: Application
    Filed: November 1, 2022
    Publication date: August 3, 2023
    Inventors: Andrew Lightfoot, Nicola Cooper, Donata Federici Canova, Roly FOULKES
  • Patent number: 11479585
    Abstract: The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: October 25, 2022
    Assignee: Revolo Biotherapeutics Limited
    Inventors: Andrew Lightfoot, Nicola Cooper, Donata Federici Canova
  • Publication number: 20220281929
    Abstract: The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
    Type: Application
    Filed: May 23, 2022
    Publication date: September 8, 2022
    Inventors: Andrew Lightfoot, Nicola Cooper, Donata Federici Canova
  • Patent number: 11098090
    Abstract: The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: August 24, 2021
    Assignee: Revolo Biotherapeutics Limited
    Inventors: Andrew Lightfoot, Nicola Cooper
  • Publication number: 20210230233
    Abstract: The present invention relates to a method for the acute treatment of a relapsing-remitting condition, the method comprising the step of administering to a subject in need thereof one or more doses of an effective amount of a peptide molecule as defined in claim 1 in response to or during a relapse, wherein the method causes remission of the condition.
    Type: Application
    Filed: January 11, 2018
    Publication date: July 29, 2021
    Inventors: Andrew Lightfoot, Nicola Cooper, Donata Federici Canova
  • Publication number: 20200071365
    Abstract: The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.
    Type: Application
    Filed: January 11, 2018
    Publication date: March 5, 2020
    Inventors: Andrew Lightfoot, Nicola Cooper
  • Patent number: 9320791
    Abstract: Peptides from the polypeptide chaperonin 60.1, and their use in medicine for the treatment of inflammatory conditions are described.
    Type: Grant
    Filed: May 14, 2014
    Date of Patent: April 26, 2016
    Assignee: PEPTINNOVATE LIMITED
    Inventors: Anthony Robert Milnes Coates, Peter Tormay, Andrew Lightfoot
  • Patent number: 9133178
    Abstract: Compounds are disclosed which modulate the ?7 nicotinic acetyl choline receptor (nAChR), having the formula (I) wherein the variables are as specified in the description and claims.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: September 15, 2015
    Assignee: Proximagen Limited
    Inventors: David Dean, Andrew Lightfoot, Susan Roomans
  • Publication number: 20150005321
    Abstract: This invention relates to modulation of the ?7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: June 4, 2014
    Publication date: January 1, 2015
    Inventors: Kevin Dinnell, Andrew Lightfoot, Gillian Elizabeth Lunniss
  • Publication number: 20140341932
    Abstract: The present invention relates to novel peptides derivable from the polypeptide chaperonin 60.1 and to their use in medicine, such as for the prevention and/or treatment of inflammatory conditions.
    Type: Application
    Filed: May 14, 2014
    Publication date: November 20, 2014
    Inventors: Anthony Robert Milnes Coates, Peter Tormay, Andrew Lightfoot
  • Patent number: 8796283
    Abstract: This invention relates to modulation of the ?7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I): or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: October 14, 2010
    Date of Patent: August 5, 2014
    Assignee: Proximagen Limited
    Inventors: Kevin Dinnell, Andrew Lightfoot, Gillian Elizabeth Lunniss
  • Publication number: 20130310380
    Abstract: Compounds are disclosed which modulate the ?7 nicotinic acetyl choline receptor (nAChR), having the formula (I) wherein the variables are as specified in the description and claims.
    Type: Application
    Filed: October 26, 2011
    Publication date: November 21, 2013
    Applicant: Proximagen Limited
    Inventors: David Dean, Andrew Lightfoot, Susan Roomans
  • Publication number: 20120283273
    Abstract: This invention relates to modulation of the ?7 nicotinic acetylcholine receptor (nAChR) by a compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: October 14, 2010
    Publication date: November 8, 2012
    Applicant: PROXIMAGEN LIMITED
    Inventors: Kevin Dinnell, Andrew Lightfoot, Gillian Elizabeth Lunniss
  • Patent number: 7504392
    Abstract: The invention provides compounds of the formula or a pharmaceutically acceptable salts thereof. The compounds are useful in therapy, in particular as antipsychotic agents.
    Type: Grant
    Filed: May 28, 2003
    Date of Patent: March 17, 2009
    Assignee: Glaxo Group Limited
    Inventors: Ian Thomson Forbes, Vincenzo Garzya, Andrew Derrick Gribble, Andrew Lightfoot, Andrew H. Payne, Graham Walker
  • Publication number: 20080269197
    Abstract: The invention provides compounds of formula (I): wherein A and B represent the groups —(CH2)m— and —(CH2)n— respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxy C1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, —(CH2)pC3-6cycloalkyl, —(CH2)pOC3-6cycloalkyl, —COC1-6alkyl, —SO2C1-6alkyl, —SOC1-6alkyl, —S—C1-6alkyl, —CO2C1-6alkyl, —CO2NR5R6, —SO2NR5R6, —(CH2)pNR5R6, —(CH2)pNR5COR6, optionally substituted aryl ring, optionally substituted heteroaryl ring or optionally substituted heterocyclyl ring; R3 represents optionally substituted aryl ring or optionally substituted heteroaryl ring; R4 represents hydrogen, hydroxy, C1-6alkyl, C1-6alkoxy, trifluoromethyl, trifluoromethoxy, halogen, —OSO2CF3, —(CH2)pC3-6cycloalkyl, —(CH2)qOC1-6alkyl or —(CH2)pOC3-6cycloalkyl; R5 and R6 each independently represent hydrogen, C1-6alkyl or, together with the nitrogen or other atoms to which they are attached, form an azacycloalky
    Type: Application
    Filed: June 24, 2008
    Publication date: October 30, 2008
    Inventors: Ian Thomson Forbes, Vincenzo Garzya, Andrew Derrick Gribble, Andrew Lightfoot, Andrew H. Payne, Graham Walker
  • Patent number: 7429579
    Abstract: The invention provides compounds of formula (I): wherein: R2 and R3 independently represent various substituents; R1 and R4 independently represent H, F, Cl, Br, C1-2alkyl, C1alkoxy, OH, CN, or NO2; B represents a sulfur atom or a —CH2-group; t represents 3 or 4; and A represents an optionally substituted 5- or 6-membered aromatic heterocyclic ring, or an optionally substituted bicyclic heterocyclic ring system in which at least the ring bound to the group B in Formula (I) is aromatic; or a salt thereof.
    Type: Grant
    Filed: November 12, 2001
    Date of Patent: September 30, 2008
    Assignee: SmithKline Beecham, PLC
    Inventors: Michael Stewart Hadley, Andrew Lightfoot, Gregor James MacDonald, Geoffrey Stemp
  • Publication number: 20070225276
    Abstract: The invention provides one or more chemical entities selected from a compound of formula (I): wherein R1 represents C1-6alkyl, C1-6alkoxy, trifluoromethyl, trifluoromethoxy, halo, cyano, 5-methyl-1,2,4-oxadiazol-3-yl or a group —SO2X; R2 represents hydrogen, C1-6alkyl, C1-6alkoxy, halo or cyano; X is C1-6alkyl, —NR3R4 or morpholino; R3 and R4 independently represent hydrogen or C1-6alkyl; and a pharmaceutically acceptable salt and solvate thereof; with the proviso that the compound {8-[4-(4-fluoro-benzyl)-benzenesulfonyl]-3-methyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-yl}-dimethyl-amine is excluded. The compounds of formula (I) and pharmaceutically acceptable salts and solvates thereof are useful in therapy, in particular as antipsychotic agents.
    Type: Application
    Filed: November 25, 2004
    Publication date: September 27, 2007
    Inventors: Ian Forbes, Gabriella Gentile, Andrew Gribble, Andrew Lightfoot, Andrew Payne, Alexander Smith
  • Publication number: 20070093473
    Abstract: The invention provides compounds of formula (I): wherein A and B represent the groups —(CH2)m— and —(CH2)n— respectively; R1 represents hydrogen or C1-6alkyl; R2 represents hydrogen, halogen, hydroxy, cyano, nitro, hydroxyC1-6alkyl, trifluoromethyl, trifluoromethoxy, C1-6alkyl, C1-6alkoxy, C1-6fluoroalkoxy, —(CH2)pC3-6cycloalkyl, —(CH2)pOC3-6cycloalkyl, —COC1-6alkyl, —SO2C1-6alkyl, —SOC1-6alkyl, —S—C1-6alkyl, —CO2C1-6alkyl, —CO2NR3R4, —SO2NR3R4, —(CH2)pNR3R4, —(CH2)pNR3COR4, optionally substituted aryl ring, optionally substituted heteroaryl ring, a fused bicyclic heteroaromatic ring system or optionally substituted heterocyclyl ring; Ar1 represents optionally substituted heteroaryl ring; Ar2 represents optionally substituted aryl ring or optionally substituted heteroaryl ring; Z represents —(CH2)qX— wherein the —(CH2)q— group is attached to Ar2, or —X(CH2)q— wherein X is attached to Ar2, and wherein any of the —CH2— groups may be optionally substituted by one or more C1-6alkyl groups; X represents
    Type: Application
    Filed: September 9, 2004
    Publication date: April 26, 2007
    Inventors: David Cooper, Ian Forbes, Vincenzo Garzya, Andrew Gribble, Andrew Lightfoot, Andrew Payne, Alexander Smith